Impact of semaglutide on cognitive function in patients with type 2 diabetes and mild cognitive impairment: a 24-month observational study.
A diabetes medication may help protect cognitive function in people with type 2 diabetes, addressing a growing concern about diabetes and dementia risk.
Type 2 diabetes mellitus (T2DM) is associated with an increased risk of mild cognitive impairment (MCI) and dementia. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide cardiovascular and metabolic benefits, and emerging data suggest neurocognitive effects.
What the study was
- Study design
- Randomized study
- Population
- patients
- Sample size
- 60
- Category
- Prevention
- Maturity
- Exploratory
- Journal
- Internal and emergency medicine
Why it surfaced
Score 7/10 [PROMISING_PRELIMINARY]: Randomized study (Journal Article) matched 'Cardiovascular-metabolic: GLP-1, SGLT2, '. Components — novelty:1/3, relevance:3/3, design:2/2, population:1/2. Confidence: high. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.